Advertisement
EXOZ vs MENS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXOZ is a Hold and MENS is a Hold.
Momentum Indicator for EXOZ turns negative, indicating new downward trend
EXOZ saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator turned negative. In 28 of the 29 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
EXOZ moved below its 50-day moving average on October 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EXOZ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXOZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for EXOZ entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXOZ advanced for three days, in 76 of 83 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
EXOZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.267) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. EXOZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXOZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MENS in +3.96% Uptrend, growing for three consecutive days on October 08, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MENS advanced for three days, in 70 of 78 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 9 of 12 cases where MENS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on MENS as a result. In 12 of 15 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for MENS just turned positive on October 08, 2026. Looking at past instances where MENS's MACD turned positive, the stock continued to rise in 4 of 6 cases over the following month. The odds of a continued upward trend are 67%.
MENS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
MENS moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MENS crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MENS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MENS entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. MENS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MENS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| EXOZ | MENS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| MACD ODDS (%) | N/A | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| Advances ODDS (%) | 21 days ago 90% | 7 days ago 90% |
| Declines ODDS (%) | 2 days ago 85% | 9 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 89% | 3 days ago 82% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXOZ’s FA Score shows that 0 FA rating(s) are green while MENS’s FA Score has 1 green FA rating(s).
- EXOZ’s FA Score: 0 green, 5 red.
- MENS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXOZ’s TA Score shows that 4 TA indicator(s) are bullish while MENS’s TA Score has 5 bullish TA indicator(s).
- EXOZ’s TA Score: 4 bullish, 5 bearish.
- MENS’s TA Score: 5 bullish, 4 bearish.
Price Growth
EXOZ (@Biotechnology) experienced а -17.39% price change this week, while MENS (@Biotechnology) price change was -0.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.52%. For the same industry, the average monthly price growth was -19.04%, and the average quarterly price growth was -19.99%.
Industries' Descriptions
@Biotechnology (-8.52% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TUA | 19.23 | -0.02 | -0.10% |
| Simplify Short Term Treasury Futures Strategy ETF (TUA) | |||
| RJDI | 29.12 | -0.04 | -0.13% |
| RJ Eagle GCM Dividend Select Income ETF (RJDI) | |||
| FEGE | 51.25 | -0.18 | -0.35% |
| FIRST EAGLE GLOBAL EQUITY ETF | |||
| TPFG | 25.15 | -0.77 | -2.96% |
| Timothy Plan Free Cash Flow Growth ETF (TPFG) | |||
| SBTU | 33.49 | -5.11 | -13.23% |
| T-REX 2X Long SBET Daily Target ETF | |||
EXOZ and
Correlation & Price change
A.I.dvisor tells us that EXOZ and CTNM have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXOZ and CTNM's prices will move in lockstep.
| Ticker / NAME | Correlation To EXOZ | 1D Price Change % | ||
|---|---|---|---|---|
| EXOZ | 100% | +0.22% | ||
| CTNM - EXOZ | 24% Poorly correlated | -3.33% | ||
| EDVA - EXOZ | 21% Poorly correlated | -0.92% | ||
| ORIC - EXOZ | 21% Poorly correlated | +2.48% | ||
| MENS - EXOZ | 11% Poorly correlated | +0.49% | ||
| LIMN - EXOZ | 9% Poorly correlated | -4.69% | ||
More | ||||
MENS and
Correlation & Price change
A.I.dvisor indicates that over the last year, MENS has been loosely correlated with VTGN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MENS jumps, then VTGN could also see price increases.
| Ticker / NAME | Correlation To MENS | 1D Price Change % | ||
|---|---|---|---|---|
| MENS | 100% | +0.49% | ||
| VTGN - MENS | 58% Loosely correlated | -3.82% | ||
| KYTX - MENS | 37% Loosely correlated | -1.47% | ||
| FDMT - MENS | 30% Poorly correlated | -1.29% | ||
| BNTC - MENS | 29% Poorly correlated | -3.94% | ||
| TRAW - MENS | 27% Poorly correlated | -2.17% | ||
More | ||||